(E)-N-methyl-3-(4-nitrophenyl)acrylamide | 141544-16-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-N-methyl-3-(4-nitrophenyl)acrylamide
• 英文别名: 4-nitro-trans-cinnamic acid methylamide；4-Nitro-trans-zimtsaeure-methylamid；(E)-N-methyl-3-(4-nitrophenyl)prop-2-enamide
• CAS: 141544-16-3
• 化学式: C₁₀H₁₀N₂O₃
• 分子量: 206.201
• InChiKey: WDJVYCKTYBDNBF-QPJJXVBHSA-N

物化性质

• 沸点：
  412.2±37.0 °C(Predicted)
• 密度：
  1.252±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-N-methyl-3-(4-nitrophenyl)acrylamide 在 盐酸 、 tin(ll) chloride 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 以64.4%的产率得到(2E)-3-(4-aminophenyl)-N-methylprop-2-enamide
  参考文献：
  名称：

  Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents

  摘要：

  A novel series of diaryl ureas containing different linker groups were designed and synthesized. Their in vitro antitumor activity against MX-1, A375, HepG2, Ketr3 and HT-29 was evaluated using the standard MIT assay. Compounds having a rigid linker group such as vinyl, ethynyl and phenyl showed significant inhibitory activity against a variety of cancer cell lines. Specifically, compound 23 with a phenyl linker group demonstrated broad-spectrum antitumor activity with IC50 values of 5.17-6.46 mu M against five tested tumor cell lines. Compound 23 is more potent than reference drug sorafenib (8.27-15.2 mu M), representing a promising lead for further optimization. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.03.020
• 作为产物：
  描述：

  对硝基肉桂酸 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 10.0h， 生成 (E)-N-methyl-3-(4-nitrophenyl)acrylamide
  参考文献：
  名称：

  Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents

  摘要：

  A novel series of diaryl ureas containing different linker groups were designed and synthesized. Their in vitro antitumor activity against MX-1, A375, HepG2, Ketr3 and HT-29 was evaluated using the standard MIT assay. Compounds having a rigid linker group such as vinyl, ethynyl and phenyl showed significant inhibitory activity against a variety of cancer cell lines. Specifically, compound 23 with a phenyl linker group demonstrated broad-spectrum antitumor activity with IC50 values of 5.17-6.46 mu M against five tested tumor cell lines. Compound 23 is more potent than reference drug sorafenib (8.27-15.2 mu M), representing a promising lead for further optimization. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.03.020

文献信息

• Mild Zinc-Promoted Horner-Wadsworth-Emmons Reactions of Diprotic Phosphonate Reagents
  作者：Paul Helquist、Douglas Schauer

  DOI：10.1055/s-2006-950292

  日期：2006.11

  We report the development of a mild protocol for the Horner-Wadsworth-Emmons reaction of diprotic phosphonates that makes use of a zinc triflate promoter in the presence of mild tertiary amine bases to produce α,β-unsaturated carboxylic acids and amides.

  我们报道了一种温和的二羧酸膦酸酯进行Horner-Wadsworth-Emmons反应的方法，该方法在温和的三级胺碱存在下利用三氟甲磺酸锌作为催化剂，生成α,β-不饱和羧酸和酰胺。
• Copper‐Catalyzed C−H (Phenylsulfonyl)difluoromethylation of Acrylamides: Scope, Mechanism, and Critical Role of Additives
  作者：Enzo Nobile、Floriane Doche、Thomas Castanheiro、Djamaladdin G. Musaev、Tatiana Besset

  DOI：10.1002/chem.202303362

  日期：2024.2.7

  Herein, we report the Cu‐complex catalyzed, native functional group‐assisted, and TFA/NMF additives promoted (phenylsulfonyl)difluoromethylation of vinylic C(sp²)−H bond of acrylamides. Using our in‐home designed reagent, this reaction enables the construction of the C(sp²)−CF₂SO₂Ph bond from simple C−H bond activation by copper catalysis under mild reaction conditions with total Z‐selectivity. The versatility of utilized fluorinated group was illustrated by its conversion into value‐added CF₂ moieties as well as the remarkable =CHF residue. The performed experimental and computational mechanistic studies enabled to identify the true nature of active catalyst and substrate, as well as establish critical roles of TFA and NMF additives. In this reaction, the TFA acts as a promoter of the much‐needed Cu^II/Cu^II→Cu^III/Cu^I disproportionation, while the NMF facilitates the following ligand exchange and C−C coupling processes. We ruled out the generation of radical intermediates and established the C−H activation to be irreversible and the rate‐determining step of the entire process.

  摘要我们在此报告了铜络合物催化、原生官能团辅助和 TFA/NMF 添加剂促进的丙烯酰胺乙烯基 C(sp2)-H键（苯磺酰基）二氟甲基化反应。利用我们自行设计的试剂，该反应可在温和的反应条件下，通过铜催化从简单的 C-H 键活化生成 C(sp2)-CF2SO2Ph 键，并具有完全的 Z 选择性。利用氟化基团将其转化为高附加值的 CF2 分子以及显著的 =CHF 残基，说明了氟化基团的多功能性。通过实验和计算机理研究，确定了活性催化剂和底物的真正性质，并确定了反式脂肪酸和 NMF 添加剂的关键作用。在这一反应中，反式脂肪酸对急需的 CuII/CuII→CuIII/CuI 歧化起到了促进作用，而 NMF 则促进了接下来的配体交换和 C-C 偶联过程。我们排除了自由基中间产物的产生，并确定 C-H 活化是不可逆的，而且是整个过程的速率决定步骤。
• Bis-tetrazolemethyl substituted beta-lactam antibiotics, their preparation and pharmaceutical formulations containing them
  申请人：ELI LILLY AND COMPANY

  公开号：EP0048165A1

  公开（公告）日：1982-03-24

  Broad spectrum β-lactam antibiotics are described. They are represented by the formula wherein R is hydrogen or an acyl group of the formula wherein R° is an aryl or aralkyl group of the formula wherein R' is phenyl or phenyl substituted by halogen, hydroxy amino, acetamido, C,-C4 alkyl, C1-C4 alkoxy, cyano, carboxy, carboxamido, carboxymethyl, C,-C4 alkoxycarbony-Imethyl, hydroxymethyl, or aminomethyl; or R' is a di- or tri-substituted phenyl group of the formula wherein each of a, a', and a" are independently hydrogen, halogen, hydroxy, C1-C4 alkyl or C1-C4 alkoxy; and or R° is an aryloxymethyl or arylthiomethyl group of the formula wherein R' has the same meanings as defined above. and z is O or S; or R° is a heterocyclic methyl group of the formula wherein R2 is thienyl, furyl, 1H-tetrazol-1-yl, 1H-tetrazol-5-yl, wherein each b is hydrogen, amino, protected-amino, C1-C3 alkyl or phenyl; or R° is a group of the formula wherein R3 is R' as defined above and in addition 1,4-cyclohexadienyl, thienyl or furyl, and Q is hydroxy, carboxy, sulfo, or amino; or R° is an oximino substituted group represented by the formula wherein R4 is R' as defined above and in addition thienyl, furyl, or wherein b has the same meanings as defined above and R5 is hydrogen, or C1-C4 alkyl; or R° is a group of the formula wherein R3 is as defined above and R6 is phenyl substituted by 1-3 hydroxy groups or pyridyl substituted with from 1-3 hydroxy groups; or R6 is a group of the formula wherein R' is C1-C4 alkylamino, phenyl, chlorophenyl, furyl, styrryl, chlorostyrryl, or nitrostyrryl; or R6 is a group of the formula wherein n' is 1 or 2 and m is 2 or 3 with the limitation that when n' is 2, m is 2; and R8 is hydrogen, C1-C3 alkyl, C2-C4 alkanoyl, or C1-C3 alkylsulfonyl; R, is hydrogen or a carboxy protecting group; R2 is hydrogen or methoxy; R3 is a bis-tetrazolemethyl group of the formula wherein R4 is hydrogen or C1-C3 alkyl; and when R, is hydrogen, the pharmaceutically acceptable salts thereof. The compounds are obtained by reacting a 7-acylamino-3-halomethyl-1-oxa-β-lactam ester with the desired 1- or 2-tetrazolemethyl substituted 1H or 2H tetrazole-5-thiol, or alternatively by reacting a 7-amino-3-halomethyl-1-oxa-b-lactam ester with the bis-tetrazole thiol and then N-acylating with the desired carboxylic acid.

  描述了广谱β-内酰胺类抗生素。它们由式 其中 R 是氢或式中的酰基 其中 R°为式中的芳基或芳烷基 其中 R' 是苯基或被卤素、羟基氨基、乙酰氨基、C,-C4 烷基、C1-C4 烷氧基、氰基、羧基、羧氨基、羧甲基、C,-C4 烷氧基羰基甲基、羟甲基或氨基甲基取代的苯基；或 R' 是式中的二取代或三取代苯基。 其中 a、a'和 a "各自独立地为氢、卤素、羟基、C1-C4 烷基或 C1-C4 烷氧基；以及 或 R° 是式中的芳氧基甲基或芳硫甲基基团 其中 R'的含义与上式定义相同，z 为 O 或 S；或 R°为式中的杂环甲基 其中 R2 是噻吩基、呋喃基、1H-四唑-1-基、1H-四唑-5-基、 其中每个 b 是氢、氨基、受保护氨基、C1-C3 烷基或苯基；或 R° 是式中的基团 其中 R3 是如上定义的 R'，此外是 1,4-环己二烯基、噻吩基或呋喃基，而 Q 是羟基、羧基、磺基或氨基；或 R°是由式所代表的草酰亚胺取代的基团 其中 R4 是如上定义的 R'，此外是噻吩基、呋喃基，或 其中 b 的含义与上式所定义的相同，R5 为氢或 C1-C4 烷基；或 R°为式中的基团 其中 R3 如上定义，R6 是被 1-3 个羟基取代的苯基或被 1-3 个羟基取代的吡啶基；或 R6 是式中的基团 其中 R'是 C1-C4 烷基氨基、苯基、氯苯基、呋喃基、苯乙烯基、氯代苯乙烯基 或硝基苯乙烯基；或 R6 是式中的基团 其中 n' 为 1 或 2，m 为 2 或 3，但当 n' 为 2 时，m 为 2；以及 R8 为氢、C1-C3 烷基、C2-C4 烷酰基或 C1-C3 烷基磺酰基；R，为氢或羧基保护基团；R2 为氢或甲氧基；R3 为式中的双四唑甲基。 其中 R4 为氢或 C1-C3 烷基；当 R 为氢时，为其药学上可接受的盐。 这些化合物是通过 7-酰氨基-3-卤甲基-1-氧杂-β-内酰胺酯与所需的 1-或 2-四唑甲基取代的 1H 或 2H 四唑-5-硫醇反应，或通过 7-氨基-3-卤甲基-1-氧杂-b-内酰胺酯与双四唑硫醇反应，然后与所需的羧酸发生 N-酰化反应而得到的。
• Bis-tetrazoylmethyl substituted cephalosporin antibiotics, their preparation and pharmaceutical formulations containing them
  申请人：ELI LILLY AND COMPANY

  公开号：EP0048169A2

  公开（公告）日：1982-03-24

  7β-Acylamino-3-cephem-4-carboxylic acids substituted in the 3-position with a bis-tetrazole-methylthiomethyl group are described. They are represented by the formula wherein R is hydrogen or an acyl group of the formula wherein R1 is C1-C4 alkyl or C1-C4 alkyl substituted by halogen or cyano; or R is an aroyl or aralkanoyl group of the formula wherein R2 is phenyl or a mono-substituted phenyl group substituted by halogen, cyano, amino, hydroxy, C1-C4 alkyl, C1-C4 alkoxy, carboxy, carboxamido, hydroxymethyl, aminomethyl, carboxymethyl, or C1-C4 alkoxycarbony-Imethyl; or R2 is a di- or tri-substituted phenyl group of the formula wherein a, a', and a" independently are hydrogen, halogen, hydroxy, C1-C4 alkoxy, provided that only one of a. a' and a" may be hydrogen, and n is 0 or 1; or R is a heteroarylalkanoyl group of the formula wherein R3 is a group of the formula wherein each b is hydrogen, amino, protected-amino, C1-C3 alkyl or phenyl; or R is an aryloxyacetyl or arylthioacetyl group of the formula wherein R2 has the same meanings as defined above and Z is 0 or S; or R is a substituted aralkanoyl or heteroarylalkanoyl group of the formula wherein R4 is R2 as defined above, and in addition is 1,4-cyclohexadienyl, thienyl or furyl, and Q is hydroxy, formyloxy, carboxy, sulfo, or amino; or R is an oximino-substituted aralkanoyl or heteroarylalkanoyl group of the formula wherein R5 is R2 and R3 as each is defined above, and R6 is hydrogen, or C1-C4 alkyl, or R is a group of the formula wherein R4 has the same meanings defined above and R' is phenyl substituted by from 1 to 3 hydroxy groups, or pyridyl substituted by from 1 to 3 hydroxy groups, or a group of the formula wherein RB is C1-C4 alkylamino, phenyl, halophenyl, furyl, styryl, nitrostyryl or halostyryl; or R7 is a group of the formula wherein n' is 1 or 2 and m is 2 or 3, with the limitation that when n' is 2, m is 2, and R9 is hydrogen, C1-C3 alkyl, C2-C4 alkanoyl, or C1-C3 alkylsulfonyl; R, is hydrogen or a carboxy protecting group; R2 is hydrogen or methoxy; R3 is a bis-tetrazolemethyl group of the formula wherein R4 is hydrogen, or C1-C3 alkyl; and when R, is hydrogen, the pharmaceutically acceptable salts thereof. The compounds are broad spectrum antibiotics useful in the treatment and control of microorganisms pathogenic to man and animals. 7β-Amino nucleus compounds represented when R is hydrogen are intermediates useful in the preparation of the antibiotics where R is acyl. The compounds are prepared by reacting a 7-amino-3- acyloxy or halo-1-oxa-β-lactam acid or ester with the appropriate bis-tetrazolemethyl thiol.

  7β-Acylamino-3-cephem-4-carboxylic acids 的 3 位被双四唑甲硫甲基取代。它们用式表示 其中 R 是氢或式中的酰基 其中 R1 是 C1-C4 烷基或被卤素或氰基取代的 C1-C4 烷基；或 R 是式中的酰基或芳酰基 其中 R2 是苯基或被卤素、氰基、氨基、羟基、C1-C4 烷基、C1-C4 烷氧基、羧基、羧酰胺基、羟甲基、氨甲基、羧甲基或 C1-C4 烷氧基羰基-甲基取代的单取代苯基；或 R2 是式中的二取代或三取代苯基。 其中 a、a'和 a "独立地为氢、卤素、羟基、C1-C4 烷氧基，但 a、a'和 a "中只能有一个为氢，且 n 为 0 或 1；或 R 为式中的杂芳基烷酰基。 其中 R3 是式中的基团 其中每个 b 是氢、氨基、受保护氨基、C1-C3 烷基或苯基；或 R 是式中的芳氧基乙酰基或芳硫基乙酰基。 其中 R2 的含义与上述定义相同，Z 为 0 或 S；或 R 为式中的取代芳烷基或杂芳基芳烷基基团 其中 R4 是如上定义的 R2，此外是 1,4-环己二烯基、噻吩基或呋喃基，且 Q 是羟基、甲酰氧基、羧基、磺基或氨基；或 R 是式中的草酰亚胺取代的假烷酰基或杂芳基假烷酰基。 其中 R5 是如上定义的 R2 和 R3，R6 是氢或 C1-C4 烷基，或 R 是式中的基团 其中 R4 具有与上式相同的定义，R'是被 1 至 3 个羟基取代的苯基，或被 1 至 3 个羟基取代的吡啶基，或一个式中的基团 其中 RB 是 C1-C4 烷基氨基、苯基、卤代苯基、呋喃基、苯乙烯基、硝基或卤代苯乙烯基；或 R7 是式中的基团 其中 n' 为 1 或 2，m 为 2 或 3，但当 n' 为 2 时，m 为 2，R9 为氢、C1-C3 烷基、C2-C4 烷酰基或 C1-C3 烷基磺酰基；R，为氢或羧基保护基；R2 为氢或甲氧基；R3 为式中的双四唑甲基基团 其中 R4 为氢或 C1-C3 烷基；当 R 为氢时，为其药学上可接受的盐。 这些化合物是广谱抗生素，可用于治疗和控制对人类和动物致病的微生物。当 R 为氢时所代表的 7β-氨基核化合物是制备 R 为酰基的抗生素的中间体。 这些化合物是通过 7-氨基-3-酰氧基或卤代-1-氧杂-β-内酰胺酸或酯与适当的双四唑甲基硫醇反应制备的。
• The Beckmann rearrangement of substituted benzylideneacetone oximes
  作者：R. E. Corbett、C. L. Davey

  DOI：10.1039/jr9550000296

  日期：——